Navigation Links
ImQuest Presentations at Keystone Symposium Focus on Advancements in Their Therapeutic and Microbicide Development Programs
Date:3/25/2009

FREDERICK, Md., March 25 /PRNewswire/ -- ImQuest Life Sciences presented their latest biological results supporting the continued development of their small molecule pyrimidinedione inhibitors of HIV-1 at the Prevention of meeting being held in Keystone, Colorado. The presentations highlighted new data supporting the selection of lead second generation therapeutic agents with an increased barrier to the selection of drug resistant virus strains in treated patients, as well as preclinical studies supporting the development of the pyrimidinedione IQP-0528 as a topical microbicide candidate for human clinical trials. The pyrimidinediones are highly potent inhibitors of HIV, exhibiting a dual mechanism of action which includes targeting virus entry and reverse transcription, a highly positive safety profile, and enhanced sensitivity against multi-drug resistant viruses isolated from patients. ImQuest recently submitted an Investigational New Drug Application to the FDA to initiate Phase 1 human clinical trials with the pyrimidinedione IQP-0410.

Robert W. Buckheit, Jr., Ph.D. (Executive Vice President and Chief Scientific Officer) presented the results of studies which demonstrate the ability of various analogs of IQP-0410 to more effectively suppress the replication of viruses which are resistant to the action of other NNRTIs used in the clinic. ImQuest, in collaboration with their drug development partner Samjin Pharmaceutical Co. Ltd of Seoul, Korea, have recently engaged in an effort to develop more active pyrimidinediones possessing this higher genetic barrier to resistance. Karen M. Watson, M.S. (Director, Topical Microbicide Research & Development) reported on results of preclinical efficacy evaluations of a series of pyrimidinediones, resulting in the selection of IQP-0528 as ImQuest's lead compound to prevent the sexual transmission of HIV worldwide. The studies included ImQuest co-authors Tracy Hartman, M.S., Lu Yang, M.D. and Christa E. Buckheit, as well as collaborators Patrick Kiser, Ph.D., Alamelu Mahalingham and Todd Johnson of The University of Utah.

"These results highlight the significant potential of the pyrimidinediones as highly potent therapeutic and preventative agents and provide additional rationale for their expedited development," said Dr. Buckheit. "We appreciate the continued support of these development programs by the National Institutes of Health (NIAID) and the International Partnership for Microbicides, as well as our close partnership with the chemistry team at Samjin."

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry.

    For further information regarding this press release please contact:
    Robert W. Buckheit, Jr., Ph.D.
    Executive Vice President and Chief Scientific Officer
    ImQuest Life Sciences, Inc.
    301-696-0274
    rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
2. SimQuest Awarded Phase 2 Contract from Office of the Secretary of Defense to Develop Pandemic Influenza Training Program
3. Accuray to Webcast Senior Management Presentations at Analyst Day Event
4. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
5. Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran
6. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
8. Inexpensive Online Pain Education Program for Physicians as Effective as Live Presentations by National Experts
9. Derma Sciences Announces Several Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming APWCA Conference
10. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
11. Trubion Announces Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... California Senate Bill (SB) 863, signed into law in ... 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , ... the study, medical payments per claim in California decreased 4 percent in 2013 and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Hamilton County, is embarking on ... LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected senior ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a ... and commercial clients in the northern Alabama and Georgia regions, is embarking on ... 1977, Nobis Works has built a network of support and education facilities to ...
(Date:12/7/2016)... ... 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting for more ... a multi-function, sealed, LED luminaire that meets the needs of everyone in the patient ... , A 2’ x 4’ model features four modes: reading, ambient, standard ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch ... gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)...  Boehringer Ingelheim announced today that it has been ... is the ninth time that the company received a ... Place to Work for LGBT Equality. Administered by the ... benchmarking report on corporate policies and practices related to ... employees. "We are committed to creating ...
Breaking Medicine Technology: